In a post by Jianda Yuan on Linkedin, it says, “Dear friends and colleagues, I hope you are enjoying the weekend with your families. We are pleased to let you know the KN495 updated clinical manuscript entitled “Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results” has been epublished by Nature Medicine on July 10.
Thank all KN-495/KeyImpaCT investigators, study team members, patients and their families for your fabulous contribution to this study which validated our checkpoint blockade immunotherapy dual biomarker finding initially published in Science in 2018.”
https://lnkd.in/eZqPtqik
Attached and available through the link please find the ePublished version for your reference: https://lnkd.in/ewdfhzE6
Source: Jianda Yuan/Linkedin
